



**ONCOCLÍNICAS DO BRASIL SERVIÇOS MÉDICOS S.A.**

CNPJ/ME nº 12.104.241/0004-02

NIRE 35.300.493.699

**Publicly Traded Company**

**MATERIAL FACT**

Oncoclínicas do Brasil Serviços Médicos SA ("Company"), in compliance with paragraph 4 of article 157 of Law 6,404/76 ("Corporate Law") and CVM Resolution 44/21, informs its shareholders and the market in general the execution of an agreement with Bioncologia de Minas S.A. to acquire the ordinary shares representing 40% of the share capital of Oncobio Serviços de Saúde S.A. ("Oncobio"), a hospital oncology treatment unit - cancer center located in Nova Lima, the great Belo Horizonte metropolitan area, Minas Gerais, for the amount of R\$41,912,172.40 ("Transaction"). After the Transaction, the Company will hold 100% of Oncobio.

Oncobio is an integrated center exclusively dedicated to high complexity multidisciplinary oncology treatment with complete hospitalization infrastructure and equipped with the most sophisticated technology in radio oncology within the concept of comprehensive cancer treatment which encompasses cancer diagnosis, treatment with and without hospitalization, surgeries and palliative care.

Oncobio's structure comprises 30 medical offices, 37 infusion positions 22 inpatient beds, a dedicated pediatric unit with 12 positions, as well as a complete structure for bone marrow transplantation (autologous and allogeneic bone), radiotherapy, oncological day care and emergency treatments.

Once the Transaction is completed, Oncobio will operate in an integrated mode with Instituto Materno Infantil de Minas Gerais S.A. (Hospital Vila da Serra), a high complexity reference hospital in Nova Lima, in Belo Horizonte metropolitan area, Minas Gerais, which is equipped with 219 hospitalization beds, complete surgical infrastructure and other medical specialties to support the cancer treatment. Hospital Vila da Serra was acquired by the Company in November 2020 by the Company and is located in a building adjacent to Oncobio unit.

The incremental adjusted EBITDA in relation to the actual levels estimated for 2022, upon synergies capture and efficiency gains resulted from the integration of such referred activities is as of approximately R\$ 20 million.

With the conclusion of the Transaction, the Company reaffirms its commitment to creating value for its shareholders, in line with the business strategy defined by its management.

The consummation of the Transaction is subject to the fulfillment of certain conditions, among which the approval by *Conselho Administrativo de Defesa Econômica* - CADE.

São Paulo, October 1st, 2021.

**Eric Alexandre Alencar**

Chief Financial and Investor Relations Officer

**ONCOCLÍNICAS DO BRASIL SERVIÇOS MÉDICOS S.A.**